Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Induction Toripalimab and Chemotherapy in Locally Advanced Cervical Cancer
NCT06093438Phase 2Recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Nov 2023
- Primary completion
- Nov 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in Cervical Cancer (CC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Started Nov 2023; status: recruiting.
02
Drugs
toripalimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT06093438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06093438.